Related Experiment Video
Updated: Apr 19, 2026
08:13
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
7.9K
A new recombinant factor VIII: from genetics to clinical use
1Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Drug Design, Development and Therapy
|December 31, 2014
Summary
Turoctocog alfa, a new recombinant coagulation factor VIII (FVIII), offers a safe therapeutic option for hemophilia A patients. Clinical trials show high safety levels and no inhibitor development, meeting patient needs.
Area of Science:
- Biotechnology
- Hematology
- Pharmacology
Background:
- Recombinant technology advances FVIII therapeutics for hemophilia A.
- Understanding FVIII biochemical characteristics drives new product development.
- Turoctocog alfa is a novel, third-generation, B-domain truncated recombinant FVIII.
Purpose of the Study:
- To review the molecular and biological properties of turoctocog alfa.
- To detail the clinical development of turoctocog alfa.
- To emphasize the needs of hemophilia A patients in relation to this therapy.
Main Methods:
- Development of turoctocog alfa using recombinant technology.
- Formulation without animal-derived or human serum components.
- Optimization of safety through specific culture conditions and a five-step purification process.
- Evaluation in two pilot clinical trials.
Main Results:
- Turoctocog alfa demonstrated high safety levels in pilot trials.
- No patients developed inhibitors during the observation period.
- The product is manufactured to high purity standards.
Conclusions:
- Turoctocog alfa represents a significant advancement in hemophilia A treatment.
- Its safety profile and manufacturing process address key patient needs.
- Further clinical development is supported by promising initial results.
Related Concept Videos
01:09Recombinant DNA
105.5K
Overview
105.5K
01:09Recombinant DNA
23.5K
23.5K
01:29Pharmacogenomics: Identification of New Drug Targets
98
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
98
01:29Venous Thrombosis III: Interprofessional Care
475
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
475
02:53Conservative Site-specific Recombination and Phase Variation
7.4K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
7.4K
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
514
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
514